Cargando…

A cohort study of antihyperglycemic medication exposure and survival in patients with gastric cancer

Objective: We aimed to estimate survival in gastric cancer patients with type 2 diabetes mellitus (T2DM) using different antihyperglycemic medication. Methods: Patients with gastric cancer and diabetes between 2003-2013 were identified form The Lithuanian Cancer Registry and The National Health Insu...

Descripción completa

Detalles Bibliográficos
Autores principales: Dulskas, Audrius, Patasius, Ausvydas, Linkeviciute-Ulinskiene, Donata, Zabuliene, Lina, Smailyte, Giedre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756873/
https://www.ncbi.nlm.nih.gov/pubmed/31518336
http://dx.doi.org/10.18632/aging.102245
_version_ 1783453481348104192
author Dulskas, Audrius
Patasius, Ausvydas
Linkeviciute-Ulinskiene, Donata
Zabuliene, Lina
Smailyte, Giedre
author_facet Dulskas, Audrius
Patasius, Ausvydas
Linkeviciute-Ulinskiene, Donata
Zabuliene, Lina
Smailyte, Giedre
author_sort Dulskas, Audrius
collection PubMed
description Objective: We aimed to estimate survival in gastric cancer patients with type 2 diabetes mellitus (T2DM) using different antihyperglycemic medication. Methods: Patients with gastric cancer and diabetes between 2003-2013 were identified form The Lithuanian Cancer Registry and The National Health Insurance Fund database. Cohort members were classified into five groups: four groups of T2DM patients according to treatment: metformin users; metformin and other medication users; sulphonylurea users; insulin and other medication users; and non-diabetic group. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate gastric cancer-specific survival and overall survival. Results: 8423 patients met eligibility criteria. Survival analysis showed no differences in gastric cancer-specific survival between non-diabetic and diabetic patient groups. Better survival was observed in the groups of patients using antihyperglycemic medication combinations with metformin, metformin alone or insulin. Lowest survival was observed in diabetic patients who were sulphonylurea users. Survival analysis comparing overall survival between non-diabetic and diabetic patients (p = 0.89) showed no evidence of survival difference between groups and survival differences between antihyperglycemic medication user groups were of borderline significance (p = 0.052). Conclusions: Antihyperglycemic medication use was not associated with a significant effect on survival in patients with gastric cancer and T2DM.
format Online
Article
Text
id pubmed-6756873
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Impact Journals
record_format MEDLINE/PubMed
spelling pubmed-67568732019-09-27 A cohort study of antihyperglycemic medication exposure and survival in patients with gastric cancer Dulskas, Audrius Patasius, Ausvydas Linkeviciute-Ulinskiene, Donata Zabuliene, Lina Smailyte, Giedre Aging (Albany NY) Research Paper Objective: We aimed to estimate survival in gastric cancer patients with type 2 diabetes mellitus (T2DM) using different antihyperglycemic medication. Methods: Patients with gastric cancer and diabetes between 2003-2013 were identified form The Lithuanian Cancer Registry and The National Health Insurance Fund database. Cohort members were classified into five groups: four groups of T2DM patients according to treatment: metformin users; metformin and other medication users; sulphonylurea users; insulin and other medication users; and non-diabetic group. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate gastric cancer-specific survival and overall survival. Results: 8423 patients met eligibility criteria. Survival analysis showed no differences in gastric cancer-specific survival between non-diabetic and diabetic patient groups. Better survival was observed in the groups of patients using antihyperglycemic medication combinations with metformin, metformin alone or insulin. Lowest survival was observed in diabetic patients who were sulphonylurea users. Survival analysis comparing overall survival between non-diabetic and diabetic patients (p = 0.89) showed no evidence of survival difference between groups and survival differences between antihyperglycemic medication user groups were of borderline significance (p = 0.052). Conclusions: Antihyperglycemic medication use was not associated with a significant effect on survival in patients with gastric cancer and T2DM. Impact Journals 2019-09-13 /pmc/articles/PMC6756873/ /pubmed/31518336 http://dx.doi.org/10.18632/aging.102245 Text en Copyright © 2019 Dulskas et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Dulskas, Audrius
Patasius, Ausvydas
Linkeviciute-Ulinskiene, Donata
Zabuliene, Lina
Smailyte, Giedre
A cohort study of antihyperglycemic medication exposure and survival in patients with gastric cancer
title A cohort study of antihyperglycemic medication exposure and survival in patients with gastric cancer
title_full A cohort study of antihyperglycemic medication exposure and survival in patients with gastric cancer
title_fullStr A cohort study of antihyperglycemic medication exposure and survival in patients with gastric cancer
title_full_unstemmed A cohort study of antihyperglycemic medication exposure and survival in patients with gastric cancer
title_short A cohort study of antihyperglycemic medication exposure and survival in patients with gastric cancer
title_sort cohort study of antihyperglycemic medication exposure and survival in patients with gastric cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756873/
https://www.ncbi.nlm.nih.gov/pubmed/31518336
http://dx.doi.org/10.18632/aging.102245
work_keys_str_mv AT dulskasaudrius acohortstudyofantihyperglycemicmedicationexposureandsurvivalinpatientswithgastriccancer
AT patasiusausvydas acohortstudyofantihyperglycemicmedicationexposureandsurvivalinpatientswithgastriccancer
AT linkeviciuteulinskienedonata acohortstudyofantihyperglycemicmedicationexposureandsurvivalinpatientswithgastriccancer
AT zabulienelina acohortstudyofantihyperglycemicmedicationexposureandsurvivalinpatientswithgastriccancer
AT smailytegiedre acohortstudyofantihyperglycemicmedicationexposureandsurvivalinpatientswithgastriccancer
AT dulskasaudrius cohortstudyofantihyperglycemicmedicationexposureandsurvivalinpatientswithgastriccancer
AT patasiusausvydas cohortstudyofantihyperglycemicmedicationexposureandsurvivalinpatientswithgastriccancer
AT linkeviciuteulinskienedonata cohortstudyofantihyperglycemicmedicationexposureandsurvivalinpatientswithgastriccancer
AT zabulienelina cohortstudyofantihyperglycemicmedicationexposureandsurvivalinpatientswithgastriccancer
AT smailytegiedre cohortstudyofantihyperglycemicmedicationexposureandsurvivalinpatientswithgastriccancer